Home Control reported a strong rebound for the year ended 31 December 2025, underpinned by higher-margin healthcare products, tighter cost control and a cleaner balance sheet.
Financial Highlights • Revenue rose 1.8% to US$109.40 million, driven by a 91.7% jump in Asian sales and a 16.3% increase in Europe, which together offset a 37.8% decline in North America. • Gross profit grew 5.8% to US$32.64 million, lifting gross margin to 29.8% from 28.7% a year earlier. • Reported net profit climbed 183.3% to US$7.10 million. Excluding restructuring, prior-year impairment and legal expenses, adjusted net profit advanced 25.8% to US$9.50 million. • Basic and diluted EPS improved to US 1.39 cents from US 0.49 cents. • The Board proposes a final dividend of US 0.66 cents per share (HK 5.19 cents), up from US 0.25 cents.
Cost & Expense Movements • Cost of sales held flat at US$76.76 million; component costs represented 87.0% of the total. • Selling and distribution expenses edged up 6.7% to US$7.79 million, while administrative expenses were stable at US$12.08 million. • Finance costs fell 73.4% to US$0.23 million after full repayment of bank borrowings. • No impairment on financial assets was booked in 2025 versus a US$3.23 million charge in 2024.
Cash Flow & Balance Sheet • Operating cash inflow reached US$7.82 million; free cash flow stood at US$7.26 million after US$0.60 million in capex. • Cash and cash equivalents rose to US$32.74 million (2024: US$19.44 million). • Interest-bearing bank loans were fully repaid; gearing ratio dropped to 0.6% (2024: 11.2%). • Net current assets more than doubled to US$34.52 million, aided by lower inventories and trade payables.
Strategic Developments • Healthcare Solutions revenue expanded to 21.4% of group sales (2024: 14.4%), reflecting the shift toward higher-margin verticals. • In June 2025, Meta-Wisdom Tech acquired a 74.0% stake, becoming the new controlling shareholder. • To accelerate growth in home-healthcare, the Group established wholly-owned subsidiary Orbiva in Hong Kong and raised US$13.68 million via a share placement in November 2025. About 70% of proceeds are earmarked for AIoT R&D and personal health-management products.
Outlook Management flags geopolitical and macroeconomic uncertainties but will maintain cost discipline while stepping up R&D, sales expansion and supply-chain optimisation to support its dual focus on smart control devices and home-healthcare solutions.
Key Dates • AGM: 12 June 2026 • Dividend record date: 30 June 2026 • Dividend payment: on or about 15 July 2026